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Abstract
The volatile anesthetic isoflurane poses a number of experimental challenges in the laboratory. Due to its rapid evaporation,
the open conditions of most in vitro electrophysiological recording systems make the determination of actual isoflurane
concentrations a challenge. Since the absolute anesthetic concentration in solution is directly related to efficacy,
concentration measurements are important to allow comparisons between laboratory and clinical studies. In this study we
quantify the sources of isoflurane loss during experimentation and describe a method for the measurement of isoflurane
concentrations using gas chromatography and mass spectrometry simultaneous to in vitro electrophysiological
measurements. Serial samples of perfused bath solution allowed correlation of isoflurane concentrations with ongoing
biological effects. Saturated physiological solutions contained 13.460.2 mM isoflurane and were diluted to desired
‘‘nominal’’ concentrations for experiments. The perfusion system established stable isoflurane concentrations within the
bath by 2 minutes. However, bath isoflurane concentrations varied substantially and unpredictably between experiments.
The magnitudes of such discrepancies in isoflurane concentrations spanned clinically important levels. Our studies suggest
that, despite countermeasures, solution handling significantly impacted the isoflurane content in the tissue bath. The
magnitude of these discrepancies appears to necessitate systematic direct measurement of bath isoflurane concentrations
during most in vitro conditions.
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Introduction
Volatile general anesthetics, such as isoflurane, facilitate
relatively rapid onset and recovery from anesthesia in the clinical
setting. However, these compounds present unique challenges for
in vitro studies of their biological effects under conditions in which
experimental access to cells generally requires open conditions. In
contrast to less volatile substances, loss of anesthetic from initial
preparation to delivery to the tissue is a potential limitation during
in vitro laboratory experiments. A calculated concentration of
anesthetic mixed in solution can be prepared to a nominal
concentration. However, in the course of an experiment, the low
partition coefficient of a volatile anesthetic for aqueous solutions
leads to phase separation and atmospheric loss from the solution.
These processes often result in important discrepancies between
nominal and actual drug concentrations in solution. In order to
characterize biological actions, a physiological response is directly
related to the concentration of the anesthetic during experiments.
Thus, unknown or variable losses in volatile anesthetic content can
lead to substantial underestimation of anesthetic efficacy.
Principally, two methods are commonly used to produce
aqueous stock solutions of volatile anesthetics. In one method,
the volatile anesthetic is added to a physiological solution and the
two separate phases are allowed to equilibrate. Aliquots from the
resulting saturated aqueous phase are then diluted to the desired
nominal test concentrations and stored in an enclosed reservoir
before delivery to the tissue bath, e.g. [1]. In the second method, a
solution reservoir holding the physiological solution is bubbled to
equilibration with vaporized isoflurane and concentrations are set
to the desired nominal concentrations by a calibrated vaporizer,
e.g. [2]. The detailed approaches to sampling from the resultant
solutions, for either method, vary greatly across studies. Important
differences between studies include the sites within the perfusion
system from which samples are taken to measure anesthetic
concentration (e.g. from the saturated source solution, the
reservoir or the bath) and the times of measurement during a
given experiment (e.g. before, during or after). Such pragmatic
differences increase the difficulty of comparing results between
studies.
As part of studies on the effects of isoflurane on glutamatergic
and GABAergic neurotransmission to brainstem neurons [3], we
implemented a serial sampling procedure of the bath solution
coincident with our electrophysiological measurements. Our
perfusion system delivered isoflurane in the range of 10 mM–
1000 mM to brain slices in the bath. In our approach, small serial
samples were taken from the bath at a site downstream from the
brain slice and isoflurane concentrations were determined by gas
chromatography/mass spectrometry (GC/MS) for correlation
with measures of synaptic transmission. Our results suggest that,
even with concerted efforts to control for procedural differences,
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on a day-to-day basis by 10–75%. The magnitude of these
differences suggests that measuring volatile anesthetics during in
vitro experiments is required to assure accurate assessments of
pharmacological results.
Materials and Methods
All animal procedures were performed with the approval of the
Institutional Animal Care and Use Committee at Oregon Health
& Science University (Portland, Oregon) and conform to the
guidelines described in the National Institutes of Health
publication ‘‘Guide for the Care and Use of Laboratory Animals’’.
Preparing aqueous isoflurane solutions
For experiments on synaptic transmission in brain slices, 20 ml
of isoflurane was added to 30 ml of physiologically formulated,
artificial cerebrospinal fluid (ACSF) containing (mM): 125 NaCl, 3
KCl, 1.2 KH2PO4, 1.2 MgSO4, 25 NaHCO3, 10 glucose, and 2
CaCl2 bubbled with 95% O2/5% CO2 (300 mOsm). This 1:1.5 v/
v mixture was placed in a glass centrifuge tube and immediately
capped with Teflon-lined cap and allowed to equilibrate at room
temperature overnight. Samples taken from the upper ACSF
phase contained 13.460.2 mM (n=8) isoflurane (see below).
Aliquots of the saturated ACSF stock were diluted in oxygenated
ACSF for use during in vitro experiments to final nominal
concentrations between 10 mM–1000 mM. In contrast, bubbling
an ACSF/isoflurane solution (600 mM) with 95% O2/5% CO2 in
an open container rapidly reduced isoflurane concentration to
50 mM after 20 min (data not shown).
Measuring isoflurane concentration by GC/MS
GC/MS determination of isoflurane concentration (Hospira,
Inc.; Lake Forest, IL) was based on modifications of a published
protocol [4]. The experimental bath was sampled (100 ml) using
gas-tight glass Hamilton syringes (Hamilton Company, Reno,
NV). Samples were immediately deposited into ice cold glass vials
containing n-heptane (500 ml, Mallinckrodt Baker, Inc.; Phillips-
burg, NJ) and the internal standard, halothane (Halocarbon
Laboratories; River Edge, NJ), then capped with Teflon-lined caps
and kept on ice. Isoflurane was extracted into the organic phase by
vortexing for 1 min. Vials were then centrifuged at 2000 rpm for
3 min to separate the phases. A 100 ml portion of the organic
phase was transferred to autosampler vials (Sun-SRi, Rockwood,
TN) and either processed immediately or stored at 280uC with
standards prepared the same day. The standard isoflurane
solutions were prepared by direct dilution with n-heptane.
Standard curves with three isoflurane concentration ranges were
used; 50–4000 mM isoflurane (bath dynamics, storage/shipping
tests); 10–1000 mM( in vitro experiments, bath dynamics); and 1–
100 mM( in vitro experiments). The internal standard (halothane)
was varied with each range and contained 1000 mM, 500 mM and
50 mM, respectively. Isoflurane concentrations were determined
from the area ratios of isoflurane/halothane compared to the
standard calibration curves prepared from known amounts of
isoflurane. On each day of experiments, bath samples were
accompanied by a set of standards and processed similarly.
Analyses were performed using a Thermo Electron TRACE
DSQ GC/MS system (Thermo Electron Corporation, Austin,
TX) configured with an AS 2000 autosampler and a split/splitless
injector. Isoflurane and halothane were separated on an AT-5ms
fused silica capillary column (30 m60.25 mm ID, 0.25 mm film
thickness, Alltech Associates, Deerfield, IL) using helium as the
carrier gas at a constant flow rate of 1 ml/min. Samples (1 ml)
were injected in the split mode with a split rate of either 1:100 or
1:200 depending on the isoflurane concentration. The injector was
maintained at 150uC and ion transfer line at 250uC. The TRACE
GC Ultra oven was held constant at 40uC for 3 min and the
temperature increased at 40uC/min to 120uC. The mass
spectrometer was operated in the electron impact mode with an
ionization energy of 70 eV and a source temperature of 250uC.
Data were acquired in the selected ion monitoring mode with ions
at m/z=117 and 148 for isoflurane and m/z=117 and 198 for
halothane. Typical retention times were 1.61 min for isoflurane
and 1.93 min for halothane. Instrument control and data
acquisition and analysis were accomplished using Xcalibur
Version 1.4 software (Thermo Scientific, Waltham, MA).
Perfusion system for brain slices
Our standard perfusion apparatus for electrophysiological
experiments was modified by the addition of 30 mL ground-glass
syringes (BD Yale/BD Luer-Lok, Franklin Lakes, NJ) to serve as
sealed reservoirs for the perfusate solutions. Reservoirs were
connected to the bath via Teflon tubing (Small Parts Inc., Miami
Lakes, FL). Reservoirs were filled completely to eliminate a
headspace gas compartment within the sealed syringe. Reservoir
syringes were mounted vertically in the perfusion apparatus with
weights fixed onto the glass syringe plungers to provide a steady
head pressure and facilitate flow. The flow rate was controlled with
a fine needle valve (FR-55S, Warner Instrument Corporation,
Hamden, CT) and maintained at 1.5 to 2 ml/min. At this flow
rate the bath volume (0.5 ml) turned over a minimum of three
times per minute. The surface area of the bath was approximately
2c m
2. Samples for isoflurane measurement were taken at fixed
times and positions within the bath (see below).
Whole cell recordings in brain slices
Brain stem slices were prepared from adult (.160 g) Sprague
Dawley rats (Charles River Laboratories, Inc., Wilmington, MA)
as described in detail previously [5]. Briefly, rats were deeply
anesthetized with isoflurane and killed by cervical dislocation. The
medulla was rapidly removed and was cut to yield a single 250 mm
thick horizontal slice. The slices were secured to the floor of the
tissue bath with a harp constructed of platinum wire and fine
polyethylene strands and perfused with ACSF at 32–35uC.
Neurons in the solitary tract nucleus (NTS) were targeted for
electrophysiological recordings [5]. Electrodes (3–4 MV) were
visually guided to neurons using infrared illumination and
differential interference contrast optics (406 water immersion
lens) on an Axioskop-2 FS plus fixed stage microscope (Zeiss,
Thornwood, NJ). The recording electrode solution contained
(mM): 10 NaCl, 130 K-gluconate, 11 EGTA, 1 CaCl2, 1 MgCl2,
10 HEPES, 2 Na2ATP, and 0.2 Na2GTP at pH 7.3 and 296
mOsm. All recordings were made in open, whole-cell patch
configuration under voltage clamp using an Axopatch 200A or
Multiclamp 700B amplifier (Axon Instruments, Foster City, CA)
and cells held at VH=260 mV. Signals were sampled at 30 kHz
and filtered at 10 kHz using p-Clamp software (version 8.2, Axon
Instruments, Foster City, CA). For data presented here, we
assessed anesthetic actions on miniature inhibitory postsynaptic
currents (mIPSCs) in second order medial NTS neurons [6] and
were isolated by blockade of EPSCs with ionotropic glutamate
receptor antagonists (2,3-dihydroxy-6-nitro-7-sulfonyl-benzo[f]-
quinoxaline, NBQX, 20 mM and D-2-amino-5-phosphonovale-
rate, AP-5; 100 mM) [7]. Miniature synaptic events were defined
by the presence of tetrodotoxin (tetrodotoxin, TTX; 3 mM). A
sensitive measure of anesthetic enhancement of GABA receptor
function is the decay-time constant of the mIPSC [3,8]. Events
Isoflurane with GABAA IPSCs
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Decatur, GA) and decay-time constants were determined by fitting
a single exponential between the 10% to 90% of peak amplitude
portions of the current decay phase.
The isoflurane test solutions were delivered to the tissue bath via
Teflon tubing and passed through a flow meter and heating
element. The bath temperature was maintained between 32 and
35uC. For each isoflurane infusion, the bath was sampled at four
time points: baseline, at 2 min before isoflurane; 2 min and 5 min
during isoflurane and 2 min following the return to control bath
solution. Slices were washed for at least 20 min following
isoflurane exposure when subsequent concentrations were tested
with the same slice preparation.
Results
Measuring isoflurane concentration in fresh and stored
bath samples by GC/MS
Isoflurane and halothane eluted in the GC/MS column at
characteristic times with signal to noise ratios greater than 10:1
(Figure 1A). The analytical method could reliably detect and
quantify isoflurane well below minimal clinically effective concen-
trations. Inter-day variability was low with relative standard
deviations ranging from 0.2 to 1.3% (Figure 1B, insert). To expand
the practicality of collecting samples over a period of days, we
assessed whether prolonged storage of extracted samples at 280uC
or shipping extracted samples impacted the measurements. To test
the stability of stored samples, solutions were prepared and
extracted as described but stored for 8 weeks at 280uC before
warming to room temperature before analysis. For the shipped
samples,isofluranesolutionswerepreparedusingidenticalprotocols
for production, sampling and extraction before being shipped
overnight on dry ice from Washington, DC to Portland, Oregon
where the GC/MS measurements were made. For these trials,
standard curves ranging from 0–4000 mM isoflurane were used.
This concentration range greatly exceeded that required for in vitro
testing (10 mM–1000 mM), as we hypothesized that discrepancies
might be exaggerated at high concentrations. The differences in
handling time and procedures of these samples (stored vs. shipped)
did not affect the standard curves (Figure 2, p=0.084 for group
comparison and p=0.808 for the interaction between the groups
and standard concentrations, two-way ANOVA).
Delivery of isoflurane to the tissue bath
Test solutions were prepared by mixing isoflurane with ACSF
(1:1.5 v/v) and this mixture was allowed to stand overnight in a
gas-tight vessel. Following the equilibration, samples from the
aqueous phase consistently contained 13.460.2 mM isoflurane
(n=8). This saturated solution of isoflurane in ACSF was then
diluted to nominal concentrations and immediately transferred to
a gas-tight reservoir. Samples taken for GC/MS measurements
directly from the reservoirs were consistently less than the nominal
concentrations calculated based on the dilution ratios (Figure 3A,
far left points) and thus represent a preparative loss of anesthetic.
In order to determine losses attributed to the delivery system and
the time necessary to alter the bath concentration, we measured
serial samples taken each minute following switching from a
control solution (isoflurane-free) to perfusion with isoflurane test
solutions (Figure 3). The concentration of isoflurane rose rapidly to
steady levels at a fixed point within the tissue bath and these levels
were maintained throughout the perfusion interval (Figure 3A).
Generally, 2 min was sufficient time to reach a steady concentra-
tion at the standard flow rates for the electrophysiological
experiments (Figure 3A). The bath isoflurane concentrations were
substantially lower than those in the sealed reservoir and this
difference represents the consistent loss of the volatile anesthetic
from the delivery system and the bath (Figure 3A). As expected,
isoflurane was lost at each stage of the protocol. Losses were
incurred during the initial dilution of stock saturated isoflurane-
ACSF and during the addition of the diluted stock to the reservoir.
However, our interest focused foremost on the concentrations in
solutions adjacent to the brain slices. From the initial saturated
solution to the sampling in the final stage of the perfusion system,
these trans-system losses were generally between 15 and 40%. For
Figure 1. Isoflurane was reliably detected and measured by
GC/MS. Bath samples (100 ml) were taken and isoflurane was extracted
into a heptane/halothane solution, where halothane served as an
internal control. A. A representative chromatogram demonstrating the
detection of isoflurane and halothane at typical retention times. The
area ratio of each peak was compared and allowed for precise
determination of isoflurane concentration. On each experimental day
bath samples were processed along side a set of standards. B. The
average of 21 standard calibration curves used during in vitro
experiments (values=mean6SEM). Standard isoflurane concentrations
and the measured area ratio of isoflurane to halothane were highly
correlated (R
2=0.99). Insert; the greatest error between the curves
occurred at 1000 mM isoflurane where the relative standard deviation
(RSD) was 1.3%. The degree of accuracy in determining bath isoflurane
concentration across experiments by GC/MS was very high.
doi:10.1371/journal.pone.0003372.g001
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nominal, 1:1 (,6.7 mM nominal), 1:3 (,3.35 mM nominal) and
1:9 (,1.3 mM nominal). Despite the losses, steady levels in the
perfusion bath were maintained so that measurements at 2 and
5 min during the electrophysiological studies accurately reflect
brain slice exposures to isoflurane. Switching to control solution
from test solutions resulted in a rapid disappearance of isoflurane
from the bath at rates similar to bath loading (Figure 3B).
Isoflurane was undetectable following 2–3 min of control
perfusion so that allowance of 20 min wash periods in the
electrophysiological studies offered an adequate margin of time for
full recovery.
Sampling during electrophysiological experiments
During electrophysiological recordings (Figure 4), mIPSC
characteristics closely corresponded to bath isoflurane concentra-
tions. Using a gas-tight glass Hamilton syringe and needle, we
sampled from the downstream outlet of the bath as a measure
most closely approximating tissue exposure (Figure 4). Sampling
produced a brief electrical artifact in the recordings that clearly
delineated the sampling interval (Figure 4B). The arrival of
isoflurane evoked a rapid increase in the mIPSC decay-time
constant that was correlated with the bath concentration of
isoflurane (Figures 4C & D). Following the return to control
solution, the mIPSC time-decay constants rapidly returned to pre-
isoflurane values (Figure 4D).
Our in vitro studies relied on the consistency of measured
concentrations of isoflurane in saturated ACSF solutions as a
starting point. We created a set of test solutions that contained
nominal isoflurane concentrations calculated from the theoretical
dilutions. This allowed us to target the range of concentrations of
interest to the synaptic studies. A plot of these nominal isoflurane
values across all trials versus the measured isoflurane bath
concentrations (Figure 5) illustrates two important points. First,
as expected, the average measured isoflurane bath concentrations
were always lower than the nominal values due to cumulative
isoflurane loss. Second, the bath concentrations varied greatly
despite uniform handling and delivery. The degree of this
variation corresponds to a range of concentrations that cross
multiple clinical levels (1 to 3 MAC, mean alveolar concentrations)
and thus could constitute a major limitation in studies in which
isoflurane is not measured.
Discussion
Here we demonstrate that a liquid/liquid extraction of
isoflurane from a typical tissue bath can be conducted simply
and effectively simultaneous with electrophysiological recordings.
Figure 2. Standard curves were constructed over a concentra-
tion range of 50 mM–4000 mM isoflurane (control, closed blue
diamonds, n=4) to test the viability of sample storage at
280uC for 8 weeks (open red circles, n=2) or shipped
overnight on dry ice (open green squares, n=5). These
procedures, storage or shipping, had no significant effect on the
accuracy of the standard curves particularly in the range of 0–1000 mM,
which was used for in vitro experiments (p=0.084 for group
comparison and p=0.808 for the interaction between the groups and
standard concentrations by two-way ANOVA).
doi:10.1371/journal.pone.0003372.g002
Figure 3. Isoflurane held in a sealed glass reservoir was plumbed to an in vitro tissue bath that was open to the atmosphere. A. In a
representative experiment, measurements from the reservoir with ACSF saturated with isoflurane (diamond, 13.4 mM) or diluted; 1:1 (triangle,
nominal concentration 6.7 mM); 1:3 (square, nominal concentration 3.35 mM) and 1:9 (circle, nominal concentration 1.3 mM) were perfused through
the bath and sampled at the bath outlet over time. There was a concentration dependent loss of isoflurane from the bath. Yet, isoflurane
concentration in the tissue bath reached a steady state after ,2 min (bath volume=0.5 ml, flow rate 1.5–2 ml/min) B. Isoflurane cleared the bath
within minutes when washed with ACSF at concentrations typically tested during in vitro electrophysiological studies.
doi:10.1371/journal.pone.0003372.g003
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closely corresponded to a physiological measure of volatile
anesthetic action (mIPSC decay time constant). The sensitivity of
the GC/MS measurements ensured accurate measurements and
yielded high resolution concentration-response relationships.
Despite rigorous procedural controls intended to consistently
deliver the fixed concentrations of isoflurane, our measurements
revealed inter-experiment variations in isoflurane delivery across a
critical range of concentrations. We observed concentration-
dependent losses of isoflurane at all stages of solution handling and
delivery. Thus, the large discrepancy between the intended,
nominal isoflurane concentration and the actual delivered
concentration raises concerns about even well-controlled delivery
protocols. Presumably the variability of these losses represents
minor differences within procedures across trials and therefore is
likely a measure of the pragmatic limits of such protocols. Our
studies clearly identify the importance of measuring the final
concentration of volatile anesthetic in the immediate vicinity of
brain slices and that such measurements are critical to defining the
biological mechanisms of action.
The accuracy and precision of isoflurane determination depend
upon minimizing sampling errors within and between experi-
ments. We attempted to control for errors in sample handling
within experiments by the addition of an internal standard as a
routine part of liquid/liquid extractions. The variance in the
standard curves generated for each study offers a measure of the
source of error between experiments. Our relative standard
deviation was maximal at the high end of our standard curves
(1 mM) and was only 1.3%.
Stock ACSF solutions saturated with isoflurane at room
temperature contained 13.460.2 mM isoflurane and this corre-
sponds to reports by others (10–15 mM) [1,9–11]. The variation in
saturated levels across these studies may be due to differences in
the composition of these extracellular solutions. Loss of volatile
anesthetics like isoflurane from a saturated aqueous solution is a
certainty with handling (diluting, mixing, and perfusing). Such
losses should be rise in proportion to the concentrations used due
to increases in the partial pressure of isoflurane in solution. For
example in our system, our highest, i.e. fully saturated, isoflurane-
ACSF solution (13.4 mM) achieved a steady state bath level of
,4.7 mM. Isoflurane likely evaporated during solution transfer to
Figure 4. Bath samples (100 mL) were taken simultaneous to
electrophysiological recordings to determine exact isoflurane
concentrations. A. In this representative example, samples were
taken from the bath 2 min before, 2 and 5 min during, and 2 min after
isoflurane exposure. The measured values indicate a rapid isoflurane
equilibration within the bath (,2 min). Isoflurane was perfused for a
total of 5 min (grey shading). B. A consequence of each sample taken
from the bath was a temporary interruption of the electrophysiological
recording (grey circular shading). This artifact provided a time stamp of
when isoflurane measurements were taken. C. Individual miniature
inhibitory post synaptic currents were elongated during isoflurane
exposure at these concentrations. D. Isoflurane concentrations in the
tissue bath, as determined by GC/MS, were precisely correlated with the
increase in the decay-time constant of miniature inhibitory post
synaptic currents (closed diamonds and open stars=events shown in
C) over the course of the experiment.
doi:10.1371/journal.pone.0003372.g004
Figure 5. The concentration of isoflurane in the bath, as
measured by GC/MS, is plotted against the nominal concen-
tration of isoflurane achieved by dilution of ACSF saturated
with isoflurane. For measured values, each point represents the
average of two samples taken during each isoflurane exposure (at 2 and
5 min, Figure 4). The range of values (grey shading) at each nominal
concentration indicates the variability of bath isoflurane concentrations.
This loss occurred consistently despite identical procedures for diluting
isoflurane to nominal concentrations for each experiment.
doi:10.1371/journal.pone.0003372.g005
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We targeted a study range of 10–1000 mM isoflurane for our
synaptic transmission studies. In this system evaporation of
isoflurane from the bath was likely facilitated by heating to 32–
35uC. Assessments of the effects of handling in other laboratories
indicated similar trends in the loss of volatile anesthetics from
aqueous solution. Diluting an aqueous solution saturated with
isoflurane (15 mM) to 2000, 1000 or 500 mM (nominal) and then
bubbling with O2/CO2 resulted in a final isoflurane concentration
of 200–300 mM in the bath [10,12]. In addition, a 20% loss
(1000 mM to 800 mM) was noted at 25uC from reservoir to bath as
measured by GC/MS [13]. Similarly, loss of drug between the
reservoir and bath where the volatile anesthetic was vaporized into
solution has been reported from 2% to 28% (isoflurane
concentrations not noted) [2,14].
Since losses of isoflurane from ACSF were inevitable, not
surprisingly, we found that measured bath concentrations of
isoflurane were lower than our nominal values calculated for our in
vitro experiments. However the degree of variability amongst
measured isoflurane samples was telling and cautionary. Our 1:79
dilution of saturated isoflurane ACSF (168 mM nominal) resulted
in bath concentrations that ranged from 54 to 129 mM( .2 fold
discrepancy). At the highest concentrations used, the 1:9 dilution
of saturated isoflurane ACSF (1340 mM nominal) resulted in bath
concentrations ranging from 323 to 1051 mM( .3 fold discrep-
ancy). Clearly, an analysis of the biological effects based on
nominal isoflurane concentrations would have not only erred in
the absolute concentration (much less) but also resulted in a high
degree of error across day to day measures. Our studies offer a
measure of the magnitude of this error that in turn contributes to
the variability of the biological effects expressed in concentration
response relationships and estimates of functional potency.
A possible alternative to intermittent sampling of the bath
perfusate uses calcium sensitive electrodes to monitor bath
concentrations continuously but relies on a indirect measure
[15]. Measures with these electrodes are influenced by pH,
osmolarity and composition of the external solution [15]. These
requirements are normally well controlled during any electro-
physiological study. Measures with these electrodes for anesthetic
detection have standard deviations of ,20% at 1 MAC isoflurane
and 35uC [15] and such precision and sensitivity may limit their
applications. Calcium sensitive electrode detection of general
anesthetics is particularly well suited to ensuring delivery of stable
isoflurane concentrations [16].
To assess current anesthetic pharmacological practices for
comparison, the published reports in the PubMed database were
surveyed by searching the first 7 months of 2008 using the terms
‘‘isoflurane’’ and ‘‘2008’’. These terms yielded 419 hits. This pool
of publications was narrowed by eliminating all clinical and whole
animal studies to focus on in vitro experiments conducted using
bath applications. Each article of the resulting 21 in vitro studies
was read to note both the methods of measuring anesthetic bath
concentration and whether the results of those measurements were
reported. Two-thirds of these reports in the Methods sections
indicated that bath or wells were sampled for GC measurement of
isoflurane concentration. However, only four articles reported
actual measured concentrations as an explicit result and two of
these cases reported only an aggregate mean isoflurane concen-
tration–essentially averaging over daily measurements. The
remaining two cases included our study[3] and did report bath
concentrations that were linked to individual trials of measured
biological effects and thus tried to draw paired comparisons of
cause and effect rather than unlinked correlates. In one-third of
the articles, no mention was made of measurements of isoflurane
concentration within the course of their report even though several
referred to earlier or pilot studies as representing assessments of
their nominal mixtures of isoflurane. Thus, most reports relied
solely on nominal concentrations to interpret their findings. Often
gas phase concentrations were monitored by infrared gas analysis,
but recent reports suggest that this approach may suffer
importantly in accuracy (+/220%) compared to GC [17].
Temperature varied widely across these preparations despite its
impact on the equilibration and biological actions of volatile
anesthetics [18]. This literature survey suggests that despite
advances in instrumentation and rigorous experimental practices,
the importance of the daily variation in delivered volatile
anesthetic is rarely reflected in reporting assessments of their
biological effects.
Our studies demonstrate that direct sampling plus the sensitivity
and accuracy of GC/MS measurements offer distinct advantages
for the study of volatile anesthetics and understanding the
variability of biological responses. Ease of setup, operational
simplicity, high precision and reliable storage of samples are all
pragmatic bonuses. Sampling at the level of the tissue from the
bath during electrophysiological recordings did require a steady
hand. Yet, GC/MS offers a rigorous and high degree of
measurement resolution in the range of the isoflurane dose
response curve of most interest, #300 mM for isoflurane near its
calculated EC50 for anesthesia [19]. Accurate measures of
anesthetic concentrations in in vitro bath solutions are essential in
in vitro experiments to assure the translation of mechanistic
observations to the clinical setting [20].
Acknowledgments
We would like to thank Jenny Luo & Dr. Andrea DeBarber of the
Bioanalytical Shared Resource & Pharmacokinetics Core at OHSU and
Dr Mark Doyle for their technical assistance.
Author Contributions
Conceived and designed the experiments: SJM JHP LL XW DRK MCA.
Performed the experiments: SJM JHP LL XW DRK. Analyzed the data:
SJM JHP LL XW DRK MCA. Wrote the paper: SJM JHP LL XW DRK
MCA.
References
1. Westphalen RI, Hemmings HC Jr (2006) Volatile anesthetic effects on glutamate
versus GABA release from isolated rat cortical nerve terminals: 4-aminopyr-
idine-evoked release. J Pharmacol Exp Ther 316: 216–223.
2. Jinks SL, Atherley RJ, Dominguez CL, Sigvardt KA, Antognini JF (2005)
Isoflurane disrupts central pattern generator activity and coordination in the
lamprey isolated spinal cord. Anesthesiology 103: 567–575.
3. Peters JH, McDougall SJ, Mendelowitz D, Koop DR, Andresen MC (2008)
Isoflurane differentially modulates inhibitory and excitatory synaptic transmis-
sion to the solitary tract nucleus. Anesthesiology 108: 675–683.
4. Kharasch ED, Thummel KE, Mautz D, Bosse S (1994) Clinical enflurane
metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 55: 434–440.
5. Doyle MW, Bailey TW, Jin Y-H, Appleyard SM, Low MJ, et al. (2004)
Strategies for cellular identification in nucleus tractus solitarius slices. J Neurosci
Methods 37: 37–48.
6. Doyle MW, Andresen MC (2001) Reliability of monosynaptic transmission in
brain stem neurons in vitro. J Neurophysiol 85: 2213–2223.
7. Jin Y-H, Bailey TW, Andresen MC (2004) Cranial afferent glutamate
heterosynaptically modulates GABA release onto second order neurons via
distinctly segregated mGluRs. J Neurosci 24: 9332–9340.
8. McDougall SJ, Bailey TW, Mendelowitz D, Andresen MC (2008) Propofol
enhances both tonic and phasic inhibitory currents in second-order neurons of
the solitary tract nucleus (NTS). Neuropharmacology 54: 552–563.
Isoflurane with GABAA IPSCs
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e33729. Scheller M, Bufler J, Schneck H, Kochs E, Franke C (1997) Isoflurane and
sevoflurane interact with the nicotinic acetylcholine receptor channels in
micromolar concentrations. Anesthesiology 86: 118–127.
10. Simon W, Hapfelmeier G, Kochs E, Zieglgansberger W, Rammes G (2001)
Isoflurane blocks synaptic plasticity in the mouse hippocampus. Anesthesiology
94: 1058–1065.
11. Westphalen RI, Hemmings HC Jr (2003) Selective depression by general
anesthetics of glutamate versus GABA release from isolated cortical nerve
terminals. J Pharmacol Exp Ther 304: 1188–1196.
12. Haseneder R, Kurz J, Dodt HU, Kochs E, Zieglgansberger W, et al. (2004)
Isoflurane reduces glutamatergic transmission in neurons in the spinal cord
superficial dorsal horn: evidence for a presynaptic site of an analgesic action.
Anesth Analg 98: 1718–1723.
13. Jones MV, Brooks PA, Harrison NL (1992) Enhancement of gamma-
aminobutyric acid-activated Cl
2 currents in cultured rat hippocampal neurones
by three volatile anaesthetics. J Physiol 449: 279–293.
14. Wu XS, Sun JY, Evers AS, Crowder M, Wu LG (2004) Isoflurane inhibits
transmitter release and the presynaptic action potential. Anesthesiology 100:
663–670.
15. Hagan CE, Pearce RA, Trudell JR, MacIver MB (1998) Concentration
measures of volatile anesthetics in the aqueous phase using calcium sensitive
electrodes. J Neurosci Methods 81: 177–184.
16. MacIver MB, Mikulec AA, Amagasu SM, Monroe FA (1996) Volatile
anesthetics depress glutamate transmission via presynaptic actions. Anesthesiol-
ogy 85: 823–834.
17. Hendrickx JF, Lemmens HJ, Carette R, De Wolf AM, Saidman LJ (2008) Can
modern infrared analyzers replace gas chromatography to measure anesthetic
vapor concentrations? BMC Anesthesiol 8: 2.
18. Franks NP, Lieb WR (1996) Temperature dependence of the potency of volatile
general anesthetics: implications for in vitro experiments. Anesthesiology 84:
716–720.
19. Franks NP, Lieb WR (1994) Molecular and cellular mechanisms of general
anaesthesia. Nature 367: 607–614.
20. Eger EI, Fisher DM, Dilger JP, Sonner JM, Evers A, et al. (2001) Relevant
concentrations of inhaled anesthetics for in vitro studies of anesthetic
mechanisms. Anesthesiology 94: 915–921.
Isoflurane with GABAA IPSCs
PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3372